e-learning
resources
Munich 2006
Monday 04.09.2006
Diagnosis and treatment in community-acquired pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficiency of two-colored magnetic-laser therapy in pneumonia
H. L. Baradzina, N. V. Manovitskaya (Minsk, Belarus)
Source:
Annual Congress 2006 - Diagnosis and treatment in community-acquired pneumonia
Session:
Diagnosis and treatment in community-acquired pneumonia
Session type:
Electronic Poster Discussion
Number:
2231
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. L. Baradzina, N. V. Manovitskaya (Minsk, Belarus). Efficiency of two-colored magnetic-laser therapy in pneumonia. Eur Respir J 2006; 28: Suppl. 50, 2231
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Two-coloured magnetic-laser therapy in sarcoidosis
Source: Eur Respir J 2005; 26: Suppl. 49, 81s
Year: 2005
Efficacy of α-tocoferol in the treatment of patients with pneumonia
Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies
Year: 2008
Safety and efficacy of CURB65 guided antibiotic therapy in community-acquired pneumonia
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010
Efficacy and safety of stepwise therapy in patients with community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 377s
Year: 2006
Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Strategies for de-escalation of therapy in patients with hospital-acquired pneumonia
Source: Eur Respir J 2007; 30: Suppl. 51, 408s
Year: 2007
Etiology and etiotropic therapy of angiogenic sepsis
Source: Eur Respir J 2003; 22: Suppl. 45, 452s
Year: 2003
Modification of empirical antibiotic therapy in community acquired pneumonia
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014
Corticosteroids as adjunctive therapy in tuberculosis pneumonia with ART
Source: Breathe 2008; 5: 274
Year: 2009
Dynamic of adherence to guidelines for antibiotic therapy of community-aquired pneumonia (CAP)
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013
Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia
Source: Eur Respir J, 50 (3) 1602306; 10.1183/13993003.02306-2016
Year: 2017
Multicolored magnetic-laser therapy in asthma patients
Source: Eur Respir J 2004; 24: Suppl. 48, 510s
Year: 2004
Efficacy of corticosteroids in hospital treated community-acquired pneumonia
Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura
Year: 2012
Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015
Comparative evaluation of timing of antibiotic intravenous-to-oral switch in pneumonia
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Inhaled antibiotics in ventilator-associated pneumonia: treatment or prophylaxis?
Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections
Year: 2016
Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia
Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections
Year: 2012
Late Breaking Abstract - Effect of adjunctive tobramycin inhalation therapy in the treatment of ventilator-associated pneumonia: findings from the randomized VAPORISE trial
Source: International Congress 2019 – Recent developments in intensive care unit medicine
Year: 2019
Frequency of side effects in antibiotic treatment for pneumonia
Source: International Congress 2019 – Clinical challenges in respiratory infection
Year: 2019
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept